Standardization of NAT for Blood-Borne Pathogens

被引:12
|
作者
Baylis, Sally A. [1 ]
Chudy, Michael [1 ]
Nuebling, C. Micha [1 ,2 ]
机构
[1] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany
[2] WHO, Essential Med & Hlth Prod Dept, CH-1211 Geneva, Switzerland
关键词
NAT; IVD; Standardization; WHO standards; International unit; ORGANIZATION INTERNATIONAL STANDARD; C VIRUS-RNA; AMPLIFICATION TECHNOLOGY NAT; PARVOVIRUS B19; WORKING REAGENTS; REFERENCE PANEL; PLASMA POOLS; HIV-1; RNA; HCV-RNA; ESTABLISH;
D O I
10.1159/000435872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Assays based on nucleic acid amplification technology (NAT) are increasingly used for screening of blood and for diagnosis or monitoring of patients. Both regulatory requirements for blood screening and international recommendations for the treatment of patients are based on common reference materials available globally for the standardization of NAT assays. World Health Organization International Standards (WHO ISs) and International Reference Panels (WHO IRPs) are primary reference materials. The characterization and manufacture of WHO reference materials as well as their evaluation is performed on behalf of the WHO by collaborating centers; their establishment is decided upon by the WHO Expert Committee on Biological Standardization (ECBS). The potency of the first WHO IS is defined by the 'international unit' (IU) which should be maintained upon replacement of the IS. The IU, unlike copy number or genome equivalent, is defined by the IS with a physical existence, is available worldwide, and allows traceability and comparability of results. The anticipated use of WHO ISs is the calibration of secondary standards or the validation of essential assay features, e.g. limit of detection. (C) 2015 S. Karger GmbH, Freiburg
引用
收藏
页码:211 / 218
页数:8
相关论文
共 50 条
  • [31] PROTECTION FROM BLOOD-BORNE PATHOGENS - VALUE AND LIMITATIONS OF UNIVERSAL PRECAUTIONS
    WONG, ES
    MARKOWITZ, SM
    [J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1993, 2 (02) : 144 - 148
  • [32] Current methods for the reduction of blood-borne pathogens: a comprehensive literature review
    Picker, Susanne M.
    [J]. BLOOD TRANSFUSION, 2013, 11 (03) : 343 - 348
  • [33] Development and psychometric validation of a scale of the compliance with blood-borne pathogens prevention
    Lee, Kyungmi
    Kang, Younhee
    [J]. APPLIED NURSING RESEARCH, 2020, 52
  • [34] BLOOD-BORNE SUBSTRATES
    KARLSSON, J
    ROSELL, S
    SALTIN, B
    [J]. ACTA PHYSIOLOGICA SCANDINAVICA, 1969, S : 14 - &
  • [35] Blood-borne infections
    Pirozzolo, Jason J.
    LeMay, Donald C.
    [J]. CLINICS IN SPORTS MEDICINE, 2007, 26 (03) : 425 - +
  • [36] Risk of transmittable blood-borne pathogens in blood units from blood donor dogs in Canada
    Nury, Charlotte
    Blais, Marie-Claude
    Arsenault, Julie
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2021, 35 (03) : 1316 - 1324
  • [38] Human immunodeficiency virus and other blood-borne viral pathogens in the athletic setting
    Anderson, SJ
    Griesemer, BA
    Johnson, MD
    Martin, TJ
    McLain, LG
    Rowland, TW
    Small, E
    LeBlanc, C
    Krein, C
    Malina, R
    Young, JC
    Liaisons, S
    Reed, FE
    Washington, RL
    Risser, WL
    [J]. PEDIATRICS, 1999, 104 (06) : 1400 - 1403
  • [39] AMSSM position statement update: blood-borne pathogens in the context of sports participation
    McGrew, Christopher
    MacCallum, Daisy-Scarlett
    Narducci, Dustymarie
    Nuti, Rathna
    Calabrese, Leonard
    Dimeff, Robert J.
    Paul, Stephen
    Poddar, Sourav
    Rao, Ashwin
    McKeag, Douglas
    [J]. BRITISH JOURNAL OF SPORTS MEDICINE, 2020, 54 (04) : 200 - 207